human genome scale crispr knockout v2 geckov2 library pooled plasmids (Azenta)
86
Structured Review
Azenta
human genome scale crispr knockout v2 geckov2 library pooled plasmids
Human Genome Scale Crispr Knockout V2 Geckov2 Library Pooled Plasmids, supplied by Azenta, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+genome+scale+crispr+knockout+v2+geckov2+library+pooled+plasmids/library+oligonucleotide+pooled/pm41577322-46-1-14
Average 86 stars, based on 1 article reviews
Human Genome Scale Crispr Knockout V2 Geckov2 Library Pooled Plasmids, supplied by Azenta, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+genome+scale+crispr+knockout+v2+geckov2+library+pooled+plasmids/library+oligonucleotide+pooled/pm41577322-46-1-14
Average 86 stars, based on 1 article reviews
human genome scale crispr knockout v2 geckov2 library pooled plasmids - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
CRISPR:Article Title: CRISPR/Cas9-based genome-wide screen reveals a synergistic effect of Irinotecan and USP1 inhibitor in colorectal cancer. Article Snippet: Irinotecan resistance remains a significant challenge in metastatic colorectal cancer (mCRC) therapy.. To address this, we identified USP1 as a synthetic lethal partner of Irinotecan through genome-wide CRISPR/Cas9 screening in HCT-116 cells.. Combining the USP1 inhibitor I-138 with Irinotecan in HCT-116, HT-29, and SW620 cell lines significantly reduced IC50, suppressed proliferation, and diminished colony formation compared to monotherapy, demonstrating a synergistic effect (combination index CI<1). Knock-Out:Article Title: CRISPR/Cas9-based genome-wide screen reveals a synergistic effect of Irinotecan and USP1 inhibitor in colorectal cancer. Article Snippet: Irinotecan resistance remains a significant challenge in metastatic colorectal cancer (mCRC) therapy.. To address this, we identified USP1 as a synthetic lethal partner of Irinotecan through genome-wide CRISPR/Cas9 screening in HCT-116 cells.. Combining the USP1 inhibitor I-138 with Irinotecan in HCT-116, HT-29, and SW620 cell lines significantly reduced IC50, suppressed proliferation, and diminished colony formation compared to monotherapy, demonstrating a synergistic effect (combination index CI<1). |